Carlsmed, Inc. (NASDAQ:CARL - Get Free Report)'s stock price traded up 7.8% on Monday. The company traded as high as $18.22 and last traded at $18.4550. 43,340 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 135,142 shares. The stock had previously closed at $17.12.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on CARL. Wall Street Zen raised shares of Carlsmed from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Needham & Company LLC lifted their price target on Carlsmed from $17.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, November 11th. BTIG Research upped their price target on Carlsmed from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, November 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Carlsmed in a research note on Wednesday, November 4th. Finally, Truist Financial raised their price objective on Carlsmed from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, November 11th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Carlsmed presently has a consensus rating of "Moderate Buy" and an average price target of $22.00.
Check Out Our Latest Stock Report on CARL
Carlsmed Price Performance
The company has a current ratio of 5.79, a quick ratio of 5.62 and a debt-to-equity ratio of 0.20. The firm has a market cap of $476.86 million, a P/E ratio of -11.76 and a beta of 1.97. The company has a fifty day moving average price of $14.97 and a two-hundred day moving average price of $12.58.
Carlsmed (NASDAQ:CARL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The company had revenue of $21.55 million during the quarter. Equities analysts anticipate that Carlsmed, Inc. will post -1.53 earnings per share for the current year.
Hedge Funds Weigh In On Carlsmed
A number of institutional investors have recently modified their holdings of CARL. Deutsche Bank AG bought a new position in Carlsmed in the 2nd quarter worth approximately $106,000. Bank of America Corp DE purchased a new position in Carlsmed during the second quarter valued at $108,000. Entropy Technologies LP purchased a new position in Carlsmed in the third quarter worth about $160,000. Alpine Woods Capital Investors LLC bought a new position in shares of Carlsmed during the second quarter valued at $161,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Carlsmed in the second quarter worth $181,000.
Carlsmed Company Profile
(
Get Free Report)
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company's products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed's platform is designed to use a patient's imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Carlsmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carlsmed wasn't on the list.
While Carlsmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.